

# GÃ¼nther Hochhaus

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5939881/publications.pdf>

Version: 2024-02-01

147  
papers

4,160  
citations

109137

35  
h-index

143772

57  
g-index

154  
all docs

154  
docs citations

154  
times ranked

3370  
citing authors

| #  | ARTICLE                                                                                                                                                                                                                                                                                                                                                         | IF  | CITATIONS |
|----|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----|-----------|
| 1  | Systematic Evaluation of the Effect of Formulation Variables on In Vitro Performance of Mometasone Furoate Suspension-Metered Dose Inhalers. AAPS Journal, 2022, 24, 9.                                                                                                                                                                                         | 2.2 | 0         |
| 2  | iBCS: 1. Principles and Framework of an Inhalation-Based Biopharmaceutics Classification System. Molecular Pharmaceutics, 2022, 19, 2032-2039.                                                                                                                                                                                                                  | 2.3 | 13        |
| 3  | iBCS: 2. Mechanistic Modeling of Pulmonary Availability of Inhaled Drugs versus Critical Product Attributes. Molecular Pharmaceutics, 2022, 19, 2040-2047.                                                                                                                                                                                                      | 2.3 | 12        |
| 4  | Dissolution and drug release. , 2021, , 225-266.                                                                                                                                                                                                                                                                                                                |     | 2         |
| 5  | Can Pharmacokinetic Studies Assess the Pulmonary Fate of Dry Powder Inhaler Formulations of Fluticasone Propionate?. AAPS Journal, 2021, 23, 48.                                                                                                                                                                                                                | 2.2 | 13        |
| 6  | Semi-mechanistic PK/PD model to assess pulmonary targeting of beclomethasone dipropionate and its active metabolite. European Journal of Pharmaceutical Sciences, 2021, 159, 105699.                                                                                                                                                                            | 1.9 | 3         |
| 7  | Optimization of the Transwell® System for Assessing the Dissolution Behavior of Orally Inhaled Drug Products through In Vitro and In Silico Approaches. Pharmaceutics, 2021, 13, 1109.                                                                                                                                                                          | 2.0 | 6         |
| 8  | Evaluation of the Sensitivity and Robustness of Modified Chi-Square Ratio Statistic for Cascade Impactor Equivalence Testing Through Monte Carlo Simulations. AAPS PharmSciTech, 2020, 21, 147.                                                                                                                                                                 | 1.5 | 0         |
| 9  | Huntington's Disease Progression: A Population Modeling Approach to Characterization Using Clinical Rating Scales. Journal of Clinical Pharmacology, 2020, 60, 1051-1060.                                                                                                                                                                                       | 1.0 | 8         |
| 10 | Urgent Appeal from International Society for Aerosols in Medicine (ISAM) During COVID-19: Clinical Decision Makers and Governmental Agencies Should Consider the Inhaled Route of Administration: A Statement from the ISAM Regulatory and Standardization Issues Networking Group. Journal of Aerosol Medicine and Pulmonary Drug Delivery, 2020, 33, 235-238. | 0.7 | 27        |
| 11 | Quantitative Assessment of Pulmonary Targeting of Inhaled Corticosteroids Using Ex Vivo Receptor Binding Studies. AAPS Journal, 2020, 22, 39.                                                                                                                                                                                                                   | 2.2 | 4         |
| 12 | Workshop Report: USP Workshop on Advancements in In Vitro Performance Testing of Drug Products. Dissolution Technologies, 2020, 27, 52-70.                                                                                                                                                                                                                      | 0.2 | 2         |
| 13 | Cascade Impactor Equivalence Testing: Comparison of the Performance of the Modified Chi-Square Ratio Statistic (mCSRS) with the Original CSRS and EMA's Average Bioequivalence Approach. AAPS PharmSciTech, 2019, 20, 249.                                                                                                                                      | 1.5 | 5         |
| 14 | Fetal Concentrations of Budesonide and Fluticasone Propionate: a Study in Mice. AAPS Journal, 2019, 21, 53.                                                                                                                                                                                                                                                     | 2.2 | 4         |
| 15 | Pharmacokinetic and pharmacodynamic modeling of gut hormone peptide YY(3-36) after pulmonary delivery. Drug Development and Industrial Pharmacy, 2019, 45, 1101-1110.                                                                                                                                                                                           | 0.9 | 1         |
| 16 | Characterization of a dextran-budesonide prodrug for inhalation therapy. European Journal of Pharmaceutical Sciences, 2019, 129, 58-67.                                                                                                                                                                                                                         | 1.9 | 13        |
| 17 | Dose Optimization Based on Pharmacokinetic-Pharmacodynamic Modeling. , 2019, , 79-120.                                                                                                                                                                                                                                                                          |     | 9         |
| 18 | Effects of lipid formulations on clove extract spray dried powders: comparison of physicochemical properties, storage stability and in vitro intestinal permeation. Pharmaceutical Development and Technology, 2018, 23, 1047-1056.                                                                                                                             | 1.1 | 2         |

| #  | ARTICLE                                                                                                                                                                                                                                              | IF  | CITATIONS |
|----|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----|-----------|
| 19 | Predicting Pulmonary Pharmacokinetics from In Vitro Properties of Dry Powder Inhalers. <i>Pharmaceutical Research</i> , 2017, 34, 2541-2556.                                                                                                         | 1.7 | 36        |
| 20 | Scope and relevance of a pulmonary biopharmaceutical classification system AAPS/FDA/USP Workshop March 16-17th, 2015 in Baltimore, MD. <i>AAPS Open</i> , 2016, 2, .                                                                                 | 0.4 | 73        |
| 21 | Cholestenolic acid, an endogenous cholesterol metabolite, is a potent $\hat{I}^3$ -secretase modulator. <i>Molecular Neurodegeneration</i> , 2015, 10, 29.                                                                                           | 4.4 | 16        |
| 22 | Evaluation of the Transwell System for Characterization of Dissolution Behavior of Inhalation Drugs: Effects of Membrane and Surfactant. <i>Molecular Pharmaceutics</i> , 2015, 12, 2618-2624.                                                       | 2.3 | 58        |
| 23 | A Systematic Analysis of the Sensitivity of Plasma Pharmacokinetics to Detect Differences in the Pulmonary Performance of Inhaled Fluticasone Propionate Products Using a Model-Based Simulation Approach. <i>AAPS Journal</i> , 2015, 17, 999-1010. | 2.2 | 13        |
| 24 | Quantitative characterization of circadian rhythm of pulmonary function in asthmatic patients treated with inhaled corticosteroids. <i>Journal of Pharmacokinetics and Pharmacodynamics</i> , 2015, 42, 391-399.                                     | 0.8 | 5         |
| 25 | Application of the Modified Chi-Square Ratio Statistic in a Stepwise Procedure for Cascade Impactor Equivalence Testing. <i>AAPS Journal</i> , 2015, 17, 370-379.                                                                                    | 2.2 | 7         |
| 26 | Pharmacokinetics and pharmacodynamics of glycopyrrolate following a continuousâ€rate infusion in the horse. <i>Journal of Veterinary Pharmacology and Therapeutics</i> , 2014, 37, 133-144.                                                          | 0.6 | 2         |
| 27 | Population Pharmacokinetic Modeling of the Unbound Levofloxacin Concentrations in Rat Plasma and Prostate Tissue Measured by Microdialysis. <i>Antimicrobial Agents and Chemotherapy</i> , 2014, 58, 678-686.                                        | 1.4 | 20        |
| 28 | Pharmacometrics in Pulmonary Diseases. <i>AAPS Advances in the Pharmaceutical Sciences Series</i> , 2014, , 349-382.                                                                                                                                 | 0.2 | 2         |
| 29 | Development of a placebo effect model combined with a dropout model for bipolar disorder. <i>Journal of Pharmacokinetics and Pharmacodynamics</i> , 2013, 40, 359-368.                                                                               | 0.8 | 13        |
| 30 | Bioequivalence of inhaled drugs: fundamentals, challenges and perspectives. <i>Therapeutic Delivery</i> , 2013, 4, 343-367.                                                                                                                          | 1.2 | 39        |
| 31 | A Stability Analysis of a Modified Version of the Chi-Square Ratio Statistic: Implications for Equivalence Testing of Aerodynamic Particle Size Distribution. <i>AAPS Journal</i> , 2013, 15, 1-9.                                                   | 2.2 | 17        |
| 32 | A Pharmacokinetic Simulation Tool for Inhaled Corticosteroids. <i>AAPS Journal</i> , 2013, 15, 159-171.                                                                                                                                              | 2.2 | 53        |
| 33 | A Sensitivity Analysis of the Modified Chi-square Ratio Statistic for Equivalence Testing of Aerodynamic Particle Size Distribution. <i>AAPS Journal</i> , 2013, 15, 465-476.                                                                        | 2.2 | 12        |
| 34 | Pharmacokinetic Evaluation of Visnagin and Ammi visnaga Aqueous Extract after Oral Administration in Rats. <i>Planta Medica</i> , 2013, 79, 312-312.                                                                                                 | 0.7 | 0         |
| 35 | Development and Validation of Liquid Chromatography-Tandem Mass Spectrometry Method for Detection and Quantification of Flunisolide in Tissue Culture Medium. <i>Analytical Letters</i> , 2013, 46, 1355-1363.                                       | 1.0 | 0         |
| 36 | Pharmacokinetic Evaluation of Visnagin and Ammi visnaga Aqueous Extract after Oral Administration in Rats. <i>Planta Medica</i> , 2012, 78, 1831-1836.                                                                                               | 0.7 | 9         |

| #  | ARTICLE                                                                                                                                                                                                                                                                        | IF  | CITATIONS |
|----|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----|-----------|
| 37 | Equivalence Considerations for Orally Inhaled Products for Local Actionâ€”ISAM/IPAC-RS European Workshop Report. <i>Journal of Aerosol Medicine and Pulmonary Drug Delivery</i> , 2012, 25, 117-139.                                                                           | 0.7 | 54        |
| 38 | Nonlinear pharmacokinetics of visnagin in rats after intravenous bolus administration. <i>European Journal of Pharmaceutical Sciences</i> , 2012, 45, 79-89.                                                                                                                   | 1.9 | 8         |
| 39 | Systemic exposure to fluticasone MDI delivered through antistatic chambers. <i>Journal of Allergy and Clinical Immunology</i> , 2011, 128, 1113-1115.e3.                                                                                                                       | 1.5 | 8         |
| 40 | Brain permeability of inhaled corticosteroids. <i>Journal of Pharmacy and Pharmacology</i> , 2010, 57, 1159-1167.                                                                                                                                                              | 1.2 | 17        |
| 41 | Laser-ablated nanofunctional polymers for the formulation of slow-release powders for dry powder inhalers: physicochemical characterization and slow-release characteristicsâ€”. <i>Journal of Pharmacy and Pharmacology</i> , 2010, 59, 1473-1484.                            | 1.2 | 3         |
| 42 | Targeting retinal and choroid neovascularization using the small molecule inhibitor carboxyamidotriazole. <i>Brain Research Bulletin</i> , 2010, 81, 320-326.                                                                                                                  | 1.4 | 10        |
| 43 | Demonstrating Bioequivalence of Locally Acting Orally Inhaled Drug Products (OIPs): Workshop Summary Report. <i>Journal of Aerosol Medicine and Pulmonary Drug Delivery</i> , 2010, 23, 1-29.                                                                                  | 0.7 | 93        |
| 44 | Budesonide and Ciclesonide: Effect of Tissue Binding on Pulmonary Receptor Binding. <i>Drug Metabolism and Disposition</i> , 2009, 37, 1421-1426.                                                                                                                              | 1.7 | 16        |
| 45 | Chronic blockade of hindbrain glucocorticoid receptors reduces blood pressure responses to novel stress and attenuates adaptation to repeated stress. <i>American Journal of Physiology - Regulatory Integrative and Comparative Physiology</i> , 2009, 296, R1445-R1454.      | 0.9 | 38        |
| 46 | Slow Release Formulations of Inhaled Rifampin. <i>AAPS Journal</i> , 2008, 10, 342-348.                                                                                                                                                                                        | 2.2 | 70        |
| 47 | Relative receptor affinity comparisons among inhaled/intranasal corticosteroids: perspectives on clinical relevance. <i>Respiratory Research</i> , 2008, 9, 75.                                                                                                                | 1.4 | 6         |
| 48 | Pharmacokinetic/pharmacodynamic profile of mometasone furoate nasal spray: Potential effects on clinical safety and efficacy. <i>Clinical Therapeutics</i> , 2008, 30, 1-13.                                                                                                   | 1.1 | 54        |
| 49 | Pharmacokinetics and Pharmacodynamics of Inhaled Glucocorticoids. <i>Journal of Asthma</i> , 2008, 45, 13-24.                                                                                                                                                                  | 0.9 | 16        |
| 50 | Simultaneous Determination of Dexamethasone, Dexamethasone 21â€”Acetate, and Paclitaxel in a Simulated Biological Matrix by RPâ€”HPLC: Assay Development and Validation. <i>Journal of Liquid Chromatography and Related Technologies</i> , 2008, 31, 1478-1491.               | 0.5 | 9         |
| 51 | Evaluation of the Administration Time Effect on the Cumulative Cortisol Suppression and Cumulative Lymphocytes Suppression for Onceâ€”Daily Inhaled Corticosteroids: A Population Modeling/Simulation Approach. <i>Journal of Clinical Pharmacology</i> , 2008, 48, 1069-1080. | 1.0 | 15        |
| 52 | Nonpeptide Somatostatin Receptor Agonists Specifically Target Ocular Neovascularization via the Somatostatin Type 2 Receptor. , 2008, 49, 5094.                                                                                                                                |     | 18        |
| 53 | Fluticasone furoate nasal spray in allergic rhinitis. <i>Drugs of Today</i> , 2008, 44, 251.                                                                                                                                                                                   | 0.7 | 1         |
| 54 | Advances in single-entity inhaled corticosteroid therapy. <i>Allergy and Asthma Proceedings</i> , 2007, 28, 125-135.                                                                                                                                                           | 1.0 | 3         |

| #  | ARTICLE                                                                                                                                                                                                                                               | IF  | CITATIONS |
|----|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----|-----------|
| 55 | Pharmacokinetic and pharmacodynamic properties important for inhaled corticosteroids. <i>Annals of Allergy, Asthma and Immunology</i> , 2007, 98, S7-S15.                                                                                             | 0.5 | 10        |
| 56 | Plasma concentrations of fluticasone propionate and budesonide following inhalation: effect of induced bronchoconstriction. <i>British Journal of Clinical Pharmacology</i> , 2007, 64, 439-444.                                                      | 1.1 | 29        |
| 57 | Pharmacokinetic/pharmacodynamic evaluation of urinary cortisol suppression after inhalation of fluticasone propionate and mometasone furoate. <i>British Journal of Clinical Pharmacology</i> , 2007, 64, 698-705.                                    | 1.1 | 17        |
| 58 | Pulmonary targeting of sustained release formulation of budesonide in neonatal rats. <i>Journal of Drug Targeting</i> , 2006, 14, 680-686.                                                                                                            | 2.1 | 11        |
| 59 | Lung bioavailability of hydrofluoroalkane fluticasone in young children when delivered by an antistatic chamber/mask. <i>Journal of Pediatrics</i> , 2006, 149, 793-797.                                                                              | 0.9 | 16        |
| 60 | Plasma concentrations of inhaled corticosteroids in relation to airflow obstruction in asthma. <i>British Journal of Clinical Pharmacology</i> , 2006, 62, 412-419.                                                                                   | 1.1 | 50        |
| 61 | Pharmacokinetic/Pharmacodynamic Modeling of Total Lymphocytes and Selected Subtypes After Oral Budesonide. <i>Journal of Pharmacokinetics and Pharmacodynamics</i> , 2006, 33, 441-459.                                                               | 0.8 | 14        |
| 62 | Differences in the glucocorticoid to progesterone receptor selectivity of inhaled glucocorticoids. <i>European Respiratory Journal</i> , 2006, 27, 511-516.                                                                                           | 3.1 | 35        |
| 63 | METABOLISM OF MOMETASONE FUROATE AND BIOLOGICAL ACTIVITY OF THE METABOLITES. <i>Drug Metabolism and Disposition</i> , 2006, 34, 225-233.                                                                                                              | 1.7 | 23        |
| 64 | CONTRARY TO ADULT, NEONATAL RATS SHOW PRONOUNCED BRAIN UPTAKE OF CORTICOSTEROIDS. <i>Drug Metabolism and Disposition</i> , 2006, 34, 939-942.                                                                                                         | 1.7 | 20        |
| 65 | A sensitive liquid chromatography-tandem mass spectrometry method for the quantification of mometasone furoate in human plasma. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2005, 819, 175-179. | 1.2 | 15        |
| 66 | Budesonide in previously untreated autoimmune hepatitis. <i>Liver International</i> , 2005, 25, 927-934.                                                                                                                                              | 1.9 | 86        |
| 67 | Pharmacokinetic/pharmacodynamic evaluation of inhalation drugs: application to targeted pulmonary delivery systems. <i>Expert Opinion on Drug Delivery</i> , 2005, 2, 519-532.                                                                        | 2.4 | 41        |
| 68 | Comparative Pharmacology, Bioavailability, Pharmacokinetics, and Pharmacodynamics of Inhaled Glucocorticosteroids. <i>Immunology and Allergy Clinics of North America</i> , 2005, 25, 469-488.                                                        | 0.7 | 94        |
| 69 | New Developments in Corticosteroids. <i>Proceedings of the American Thoracic Society</i> , 2004, 1, 269-274.                                                                                                                                          | 3.5 | 39        |
| 70 | In Vitro and in Vivo Anti-Inflammatory Activity of the New Glucocorticoid Ciclesonide. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2004, 309, 249-258.                                                                             | 1.3 | 102       |
| 71 | How the Lung Handles Drugs: Pharmacokinetics and Pharmacodynamics of Inhaled Corticosteroids. <i>Proceedings of the American Thoracic Society</i> , 2004, 1, 356-363.                                                                                 | 3.5 | 98        |
| 72 | In Vitro Performance Characteristics of Valved Holding Chamber and Spacer Devices with a Fluticasone Metered-Dose Inhaler. <i>Pharmacotherapy</i> , 2004, 24, 159-166.                                                                                | 1.2 | 11        |

| #  | ARTICLE                                                                                                                                                                                                                                                                                                                                                                                | IF  | CITATIONS |
|----|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----|-----------|
| 73 | Stabilized dynorphin derivatives for modulating antinociceptive activity in morphine tolerant rats: Effect of different routes of administration. <i>AAPS Journal</i> , 2004, 6, 68-73.                                                                                                                                                                                                | 2.2 | 17        |
| 74 | Identification of Stabilized Dynorphin Derivatives for Suppressing Tolerance in Morphine-Dependent Rats. <i>Pharmaceutical Research</i> , 2004, 21, 1450-1456.                                                                                                                                                                                                                         | 1.7 | 7         |
| 75 | Pharmacokinetic aspects of biotechnology products. <i>Journal of Pharmaceutical Sciences</i> , 2004, 93, 2184-2204.                                                                                                                                                                                                                                                                    | 1.6 | 268       |
| 76 | Simultaneous quantification of beclomethasone dipropionate and its metabolite, beclomethasone 17-monopropionate in rat and human plasma and different rat tissues by liquid chromatography- $\alpha$ -positive electrospray ionization tandem mass spectrometry. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2004, 805, 203-210. | 1.2 | 9         |
| 77 | A Novel Method for Polymer Coating of Plasmid DNA: Initial Investigations into the Use of Pulse Laser Deposition and Gene Delivery. <i>Journal of Drug Targeting</i> , 2004, 12, 237-241.                                                                                                                                                                                              | 2.1 | 1         |
| 78 | Intranasal Lofeprednol Etabonate in Healthy Male Subjects: Pharmacokinetics and Effects on Endogenous Cortisol. <i>Journal of Clinical Pharmacology</i> , 2004, 44, 510-519.                                                                                                                                                                                                           | 1.0 | 8         |
| 79 | Drugs used in the treatment of opioid tolerance and physical dependence: a review. <i>International Journal of Clinical Pharmacology and Therapeutics</i> , 2004, 42, 191-203.                                                                                                                                                                                                         | 0.3 | 54        |
| 80 | In Vitro Performance of Two Common Valved Holding Chambers with a Chlorofluorocarbon-Free Beclomethasone Metered-Dose Inhaler. <i>Pharmacotherapy</i> , 2003, 23, 1538-1544.                                                                                                                                                                                                           | 1.2 | 12        |
| 81 | SPE/RIA vs LC/MS for measurement of low levels of budesonide in plasma. <i>Biomedical Chromatography</i> , 2003, 17, 14-20.                                                                                                                                                                                                                                                            | 0.8 | 10        |
| 82 | Simultaneous quantification of budesonide and its two metabolites, 6 $\beta$ -hydroxybudesonide and 16 $\beta$ -hydroxyprednisolone, in human plasma by liquid chromatography negative electrospray ionization tandem mass spectrometry. <i>Biomedical Chromatography</i> , 2003, 17, 158-164.                                                                                         | 0.8 | 23        |
| 83 | Validation of a simple liquid chromatography assay for creatine suitable for pharmacokinetic applications, determination of plasma protein binding and verification of percent labeled claim of various creatine products. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2003, 794, 157-165.                                       | 1.2 | 20        |
| 84 | Pharmacokinetics of the Dietary Supplement Creatine. <i>Clinical Pharmacokinetics</i> , 2003, 42, 557-574.                                                                                                                                                                                                                                                                             | 1.6 | 93        |
| 85 | Single- and Multiple-Dose Pharmacokinetics of Oral Creatine. <i>Journal of Clinical Pharmacology</i> , 2003, 43, 29-37.                                                                                                                                                                                                                                                                | 1.0 | 39        |
| 86 | Performance of a Corticosteroid Inhaler with a Spacer Fashioned from a Plastic Cold-Drink Bottle: Effects of Changing Bottle Volume. <i>Journal of Asthma</i> , 2003, 40, 237-242.                                                                                                                                                                                                     | 0.9 | 5         |
| 87 | Population Pharmacokinetics and Pharmacodynamics of Ciclesonide. <i>Journal of Clinical Pharmacology</i> , 2003, 43, 365-378.                                                                                                                                                                                                                                                          | 1.0 | 96        |
| 88 | Pharmacodynamics of omalizumab: implications for optimised dosing strategies and clinical efficacy in the treatment of allergic asthma. <i>Current Medical Research and Opinion</i> , 2003, 19, 491-499.                                                                                                                                                                               | 0.9 | 177       |
| 89 | In Vitro Comparison of Fluticasone Respirable Dose From a Metered-Dose Inhaler and Three Ridged Valved Holding Chamber. <i>Chest</i> , 2003, 124, 137S.                                                                                                                                                                                                                                | 0.4 | 0         |
| 90 | A New Solution-Based Intranasal Triamcinolone Acetonide Formulation in Patients with Perennial Allergic Rhinitis: How Does the Pharmacokinetic/Pharmacodynamic Profile for Cortisol Suppression Compare with an Aqueous Suspension-Based Formulation?. <i>Journal of Clinical Pharmacology</i> , 2002, 42, 662-669.                                                                    | 1.0 | 7         |

| #   | ARTICLE                                                                                                                                                                                                                                                                                                              | IF  | CITATIONS |
|-----|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----|-----------|
| 91  | In vitro deposition of fluticasone aerosol from a metered-dose inhaler with and without two common valved holding chambers. <i>Annals of Allergy, Asthma and Immunology</i> , 2002, 88, 204-208.                                                                                                                     | 0.5 | 12        |
| 92  | Differences in Inhaled Fluticasone Bioavailability Between Holding Chambers in Children with Asthma. <i>Pharmacotherapy</i> , 2002, 22, 947-953.                                                                                                                                                                     | 1.2 | 13        |
| 93  | Pharmacokinetics of plasmid DNA in the rat. <i>Pharmaceutical Research</i> , 2001, 18, 67-74.                                                                                                                                                                                                                        | 1.7 | 33        |
| 94  | Receptor binding studies of soft anticholinergic agents. <i>AAPS PharmSci</i> , 2001, 3, 44-56.                                                                                                                                                                                                                      | 1.3 | 36        |
| 95  | Methods used to assess pulmonary deposition and absorption of drugs. <i>Drug Discovery Today</i> , 2001, 6, 367-375.                                                                                                                                                                                                 | 3.2 | 58        |
| 96  | Pharmacokinetics and Rectal Bioavailability of Hydrocortisone Acetate after Single and Multiple Administration in Healthy Subjects and Patients. <i>Journal of Clinical Pharmacology</i> , 2001, 41, 536-541.                                                                                                        | 1.0 | 13        |
| 97  | Pharmacokinetics and Pharmacodynamics of Dexamethasone Sodium-m-Sulfobenzoate (DS) after Intravenous and Intramuscular Administration: A Comparison with Dexamethasone Phosphate (DP). <i>Journal of Clinical Pharmacology</i> , 2001, 41, 425-434.                                                                  | 1.0 | 39        |
| 98  | Single-Dose and Steady-State Pharmacokinetic and Pharmacodynamic Evaluation of Therapeutically Clinically Equivalent Doses of Inhaled Fluticasone Propionate and Budesonide, Given as Diskus® or Turbohaler® Dry-Powder Inhalers to Healthy Subjects. <i>Journal of Clinical Pharmacology</i> , 2001, 41, 1329-1338. | 1.0 | 34        |
| 99  | Pharmacokinetic Considerations in the Design of Pulmonary Drug Delivery Systems for Glucocorticoids. <i>Drugs and the Pharmaceutical Sciences</i> , 2001, , .                                                                                                                                                        | 0.1 | 2         |
| 100 | Evolution of Pharmacokinetics and Pharmacokinetic/Dynamic Correlations during the 20th Century. <i>Journal of Clinical Pharmacology</i> , 2000, 40, 908-917.                                                                                                                                                         | 1.0 | 20        |
| 101 | A sensitive LC-MS/MS method for the quantification of fluticasone propionate in human plasma. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2000, 22, 123-129.                                                                                                                                          | 1.4 | 36        |
| 102 | An interactive algorithm for the assessment of cumulative cortisol suppression during inhaled corticosteroid therapy. <i>AAPS PharmSci</i> , 2000, 2, 28-37.                                                                                                                                                         | 1.3 | 15        |
| 103 | Analysis of leucine enkephalin by high-performance liquid chromatography using enzymatic derivatization by tyrosinase and electrochemical or fluorescence detection. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 1999, 19, 855-864.                                                                   | 1.4 | 9         |
| 104 | Assessment of complex peptide degradation pathways via structured multicompartmental modeling approaches: The metabolism of dynorphin A(1-13) and related fragments in human plasma. <i>Journal of Pharmaceutical Sciences</i> , 1999, 88, 938-944.                                                                  | 1.6 | 6         |
| 105 | A pharmacokinetic/pharmacodynamic approach to predict the cumulative cortisol suppression of inhaled corticosteroids. <i>Journal of Pharmacokinetics and Pharmacodynamics</i> , 1999, 27, 127-147.                                                                                                                   | 0.6 | 17        |
| 106 | Kinetic modeling of plasmid DNA degradation in rat plasma. <i>AAPS PharmSci</i> , 1999, 1, 15-20.                                                                                                                                                                                                                    | 1.3 | 53        |
| 107 | Pharmacokinetics of intravenous dynorphin A(1-13) in opioid-naïve and opioid-treated human volunteers*. <i>Clinical Pharmacology and Therapeutics</i> , 1998, 64, 27-38.                                                                                                                                             | 2.3 | 16        |
| 108 | Effect of dose and release rate on pulmonary targeting of liposomal triamcinolone acetonide phosphate. <i>Pharmaceutical Research</i> , 1998, 15, 461-465.                                                                                                                                                           | 1.7 | 34        |

| #   | ARTICLE                                                                                                                                                                                                                               | IF  | CITATIONS |
|-----|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----|-----------|
| 109 | Pharmacokinetic and pharmacodynamic evaluation of fluticasone propionate after inhaled administration. <i>European Journal of Clinical Pharmacology</i> , 1998, 53, 459-467.                                                          | 0.8 | 65        |
| 110 | A selective HPLC/RIA for the determination of budesonide. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 1998, 17, 1235-1242.                                                                                             | 1.4 | 12        |
| 111 | Dependency of Cortisol Suppression on the Administration Time of Inhaled Corticosteroids. <i>Journal of Clinical Pharmacology</i> , 1997, 37, 704-710.                                                                                | 1.0 | 30        |
| 112 | Pharmacokinetic/Pharmacodynamic Aspects of Aerosol Therapy using Glucocorticoids as a Model. <i>Journal of Clinical Pharmacology</i> , 1997, 37, 881-892.                                                                             | 1.0 | 96        |
| 113 | Pharmacokinetic/Pharmacodynamic Evaluation of Systemic Effects of Flunisolide after Inhalation. <i>Journal of Clinical Pharmacology</i> , 1997, 37, 893-903.                                                                          | 1.0 | 24        |
| 114 | Pharmacokinetics of Methylprednisolone and Prednisolone After Single and Multiple Oral Administration. <i>Journal of Clinical Pharmacology</i> , 1997, 37, 916-925.                                                                   | 1.0 | 55        |
| 115 | An HPLC/RIA method for dynorphin A1-13 and its main metabolites in human blood. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 1997, 16, 101-109.                                                                         | 1.4 | 6         |
| 116 | Pulmonary targeting of liposomal triamcinolone acetonide phosphate. <i>Pharmaceutical Research</i> , 1996, 13, 1699-1703.                                                                                                             | 1.7 | 32        |
| 117 | Metabolism of dynorphin A1-13 in human CSF. <i>Neurochemical Research</i> , 1996, 21, 1213-1219.                                                                                                                                      | 1.6 | 11        |
| 118 | Metabolism of dynorphin A 1-13 in human blood and plasma. <i>Pharmaceutical Research</i> , 1995, 12, 1165-1170.                                                                                                                       | 1.7 | 29        |
| 119 | Assessment of glucocorticoid lung targeting by ex-vivo receptor binding studies in rats. <i>Pharmaceutical Research</i> , 1995, 12, 134-137.                                                                                          | 1.7 | 29        |
| 120 | Pharmacokinetic/pharmacodynamic evaluation of deflazacort in comparison to methylprednisolone and prednisolone. <i>Pharmaceutical Research</i> , 1995, 12, 1096-1100.                                                                 | 1.7 | 48        |
| 121 | Pharmacokinetics of Triamcinolone Acetonide After Intravenous, Oral, and Inhaled Administration. <i>Journal of Clinical Pharmacology</i> , 1995, 35, 302-305.                                                                         | 1.0 | 100       |
| 122 | Pharmacokinetic and Pharmacodynamic Evaluation of Triamcinolone Acetonide After Intravenous, Oral, and Inhaled Administration. <i>Journal of Clinical Pharmacology</i> , 1995, 35, 1187-1193.                                         | 1.0 | 51        |
| 123 | Response to the Commentary on "Pharmacokinetic Characterization and Tissue Distribution of the New Glucocorticoid Soft Drug Loteprednol Etaponate in Rats and Dogs". <i>Journal of Pharmaceutical Sciences</i> , 1994, 83, 1067-1068. | 1.6 | 1         |
| 124 | Leucine enkephalin-tyrosinase reaction products - Identification and biological activity. <i>Biochimica Et Biophysica Acta - Molecular Cell Research</i> , 1994, 1222, 95-100.                                                        | 1.9 | 5         |
| 125 | P149 new electrochemical and fluoregenic assays for leucine enkephalin based on enzymatic derivatization by tyrosinase. <i>European Journal of Pharmaceutical Sciences</i> , 1994, 2, 156.                                            | 1.9 | 0         |
| 126 | P140 a selective HPLC/RIA assay for budesonide in biological fluids. <i>European Journal of Pharmaceutical Sciences</i> , 1994, 2, 153.                                                                                               | 1.9 | 0         |



| #   | ARTICLE                                                                                                                                                                                              | IF  | CITATIONS |
|-----|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----|-----------|
| 127 | P225 metabolism of DYN a 1â€“13 in human plasma. European Journal of Pharmaceutical Sciences, 1994, 2, 175.                                                                                          | 1.9 | 0         |
| 128 | Clinical Pharmacology of Pancreatic Enzymes in Patients with Cystic Fibrosis and <i>In Vitro</i> Performance of Microencapsulated Formulations. Journal of Clinical Pharmacology, 1994, 34, 158-166. | 1.0 | 59        |
| 129 | PK/PD analysis of albuterol action: application to a comparative assessment of Î²2-adrenergic drugs. European Journal of Pharmaceutical Sciences, 1993, 1, 73-80.                                    | 1.9 | 0         |
| 130 | Receptorâ€“Based Pharmacokineticâ€“Pharmacodynamic Analysis of Corticosteroids. Journal of Clinical Pharmacology, 1993, 33, 115-123.                                                                 | 1.0 | 120       |
| 131 | Pharmacokinetic/dynamic correlation of pulmonary and cardiac effects of fenoterol in asthmatic patients after different routes of administration. Pharmaceutical Research, 1992, 09, 291-297.        | 1.7 | 26        |
| 132 | A Selective HPLC/RIA for dexamethasone and its prodrug dexamethasone-21-sulphobenzoate sodium in biological fluids. Biomedical Chromatography, 1992, 6, 283-286.                                     | 0.8 | 8         |
| 133 | Pharmacokinetic Characterization and Tissue Distribution of the New Glucocorticoid Soft Drug Loteprednol Etabonate in Rats and Dogs. Journal of Pharmaceutical Sciences, 1992, 81, 1210-1215.        | 1.6 | 38        |
| 134 | cAMP accumulation in opioid-sensitive SH-SY5Y neuroblastoma cells is modified by estradiol and progesterone. Molecular and Cellular Endocrinology, 1991, 78, 155-162.                                | 1.6 | 15        |
| 135 | Soft drugsâ€”10. Blanching activity and receptor binding affinity of a new type of glucocorticoid: Loteprednol etabonate. Journal of Steroid Biochemistry and Molecular Biology, 1991, 38, 149-154.  | 1.2 | 93        |
| 136 | A new fluorogenic assay for tyrosine-containing peptides. Journal of Pharmaceutical and Biomedical Analysis, 1991, 9, 557-563.                                                                       | 1.4 | 3         |
| 137 | A selective LC/RIA for dexamethasone and its prodrug dexamethasone-21-isonicotinate in biological fluids. Journal of Pharmaceutical and Biomedical Analysis, 1991, 9, 761-767.                       | 1.4 | 10        |
| 138 | Oral bioavailability of triamcinolone tablets and a triamcinolone diacetate suspension. Pharmaceutical Research, 1990, 07, 558-560.                                                                  | 1.7 | 3         |
| 139 | Binding affinities of rimexolone (ORG 6216), flunisolide and their putative metabolites for the glucocorticoid receptor of human synovial tissue. Agents and Actions, 1990, 30, 377-380.             | 0.7 | 15        |
| 140 | An avidinâ€”biotin based enzyme-linked immunosorbent assay for dynorphin A 1â€“13. Journal of Pharmaceutical and Biomedical Analysis, 1990, 8, 541-545.                                              | 1.4 | 0         |
| 141 | [Biocytin13]dynorphin A 1-13 amide: a potential probe for the kappa-opioid receptor. Pharmaceutical Research, 1988, 05, 790-794.                                                                     | 1.7 | 5         |
| 142 | A biotin-avidin-based enzyme immunoassay for beta h-endorphin. Pharmaceutical Research, 1988, 05, 232-235.                                                                                           | 1.7 | 4         |
| 143 | Delta opioid receptor in human neuroblastoma cell lines. Brain Research, 1986, 382, 327-331.                                                                                                         | 1.1 | 23        |
| 144 | HPLC determination of glucocorticoid alcohols, their phosphates and hydrocortisone in aqueous solutions and biological fluids. Journal of Pharmaceutical and Biomedical Analysis, 1986, 4, 197-206.  | 1.4 | 50        |

| #   | ARTICLE                                                                                                                                                                    | IF  | CITATIONS |
|-----|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----|-----------|
| 145 | Affinities of glucocorticoids for glucocorticoid receptors in the human lung. Agents and Actions, 1986, 17, 290-291.                                                       | 0.7 | 26        |
| 146 | Simultaneous determination of glucocorticoid alcohols, their succinates and hydrocortisone in plasma. Journal of Pharmaceutical and Biomedical Analysis, 1985, 3, 566-573. | 1.4 | 12        |
| 147 | Identification of glucocorticoid receptors in normal and neoplastic adult human lung. Research in Experimental Medicine, 1983, 182, 71-78.                                 | 0.7 | 13        |